30 July 2013 | News | By BioSpectrum Bureau
Daiichi Sankyo is seeking to work with new partners to research and discover new drug candidates.
Singapore: Japan-based Daiichi Sankyo has decided to expand its collaborative drug discovery program with universities and research institutions based in Japan, 'Take a New challenge for Drug diScovery (TaNeDS) Global Program,' to Germany, Switzerland and Austria. Currently, the company is seeking to work with new partners to research and discover new drug candidates.
Researchers who can conduct research in Germany, Switzerland and Austria on novel projects that match Daiichi's requirements can participate in this program. The research themes include antibody drugs for cancer, small-molecule cancer therapeutics, new treatments for diabetes and complications of diabetes, novel mechanisms for genetic disorders, target molecules and delivery systems for nucleic acid treatments, and protein x-ray crystallography technology.
The universities, research institutes and start-up companies will be chosen by Daiichi Sankyo and its wholly-owned subsidiary, a German-based U3 Pharma.
Earlier in 2011, the TaNeDS collaborative drug discovery project was launched in Japan to help discover new lines of research through open innovation.